REDWOOD CITY, Calif., May 2 /PRNewswire-FirstCall/ -- Genitope Corporation today announced that data from its ongoing Phase 2 clinical trial evaluating MyVax(R) personalized immunotherapy following rituximab as a treatment for follicular Non-Hodgkin’s Lymphoma (fNHL) has been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting in Atlanta, Georgia on Monday, June 5, 2006.
“This trial is part of Genitope Corporation’s systematic approach to exploring all clinical options for integrating MyVax(R) personalized immunotherapy into current treatment trends, including its use with existing monoclonal antibody-based treatments for fNHL,” said Dan W. Denney, Jr., Ph.D., chief executive officer of Genitope Corporation.
Data presented at ASCO will include B-cell counts and humoral immune response data from patients who were treated with rituximab and MyVax(R) personalized immunotherapy after failing to achieve a partial remission with chemotherapy.
“Given the widespread use of rituximab for treating fNHL, we are intensely interested in understanding how its mechanism of action interacts with that of MyVax(R) personalized immunotherapy, and in determining a regimen that maximizes the benefit patients derive from each therapy,” Denney said.
In addition to clinical trials in fNHL, Genitope Corporation is also exploring the use of MyVax(R) personal immunotherapy to treat other types of cancers. In February of this year, the company initiated a Phase 2 trial for patients with previously untreated chronic lymphocytic leukemia (CLL). CLL is a type of cancer affecting the blood and bone marrow and affects 70,000 people nationwide. Genitope Corporation anticipates that this clinical trial will enroll patients at nine centers across the United States.
About Genitope Corporation
Genitope Corporation (Redwood City, Calif.) is a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. Genitope Corporation’s lead product candidate, MyVax(R) personalized immunotherapy, is a patient-specific active immunotherapy based on the unique genetic makeup of a patient’s tumor and is designed to activate the patient’s immune system to identify and attack cancer cells. For more information on the company, please log on to http://www.genitope.com.
Forward Looking Statements
This news release contains “forward-looking statements.” For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements, including statements about data from the Phase 2 clinical trial to be presented in June at the ASCO annual meeting and the anticipated timing, scope and potential outcome of Genitope Corporation’s Phase I/II clinical trial of MyVax(R) personalized immunotherapy for the treatment of CLL. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Genitope Corporation’s results to differ materially from those indicated by these forward-looking statements, including without limitation, risks relating to the progress, timing and results of Genitope Corporation’s clinical trials and other research and development activities, risks relating to the manufacturing of MyVax(R) personalized immunotherapy and other risks detailed in Genitope Corporation’s filings with the Securities and Exchange Commission, including under the heading “Risk Factors” in the Annual Report on Form 10-K for the fiscal year ended December 31, 2005 filed by Genitope Corporation with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date of this press release. Genitope Corporation undertakes no obligation to revise or update any forward- looking statements to reflect events or circumstances after the date hereof.
Media Contact: Amy Meshulam Edelman P: 323.202.1065 amy.meshulam@edelman.com Investor Contact: John Vuko Chief Financial Officer, Genitope Corporation P: 650.482.2000 IR@genitope.com
Genitope Corporation
CONTACT: Media: Amy Meshulam of Edelman, +1-323-202-1065,amy.meshulam@edelman.com; or John Vuko, Chief Financial Officer of GenitopeCorporation, +1-650-482-2000, IR@genitope.com
Web site: http://www.genitope.com/
